CN102046199A - 使用抗mif抗体的治疗方法 - Google Patents

使用抗mif抗体的治疗方法 Download PDF

Info

Publication number
CN102046199A
CN102046199A CN200980109905XA CN200980109905A CN102046199A CN 102046199 A CN102046199 A CN 102046199A CN 200980109905X A CN200980109905X A CN 200980109905XA CN 200980109905 A CN200980109905 A CN 200980109905A CN 102046199 A CN102046199 A CN 102046199A
Authority
CN
China
Prior art keywords
mif
antibody
cxcr2
antibodies
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980109905XA
Other languages
English (en)
Chinese (zh)
Inventor
于尔根·伯恩哈根
乔舒亚·罗伯特·舒尔茨
贝内迪克特·福尔拉特
阿尔玛·策内克
克里斯蒂安·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carolus Therapeutics Inc
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of CN102046199A publication Critical patent/CN102046199A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN200980109905XA 2008-03-20 2009-03-20 使用抗mif抗体的治疗方法 Pending CN102046199A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US3838108P 2008-03-20 2008-03-20
US61/038,381 2008-03-20
US3937108P 2008-03-25 2008-03-25
US61/039,371 2008-03-25
US4580708P 2008-04-17 2008-04-17
US61/045,807 2008-04-17
US12109508P 2008-12-09 2008-12-09
US61/121,095 2008-12-09
PCT/US2009/037883 WO2009117706A2 (en) 2008-03-20 2009-03-20 Methods of treatment using anti-mif antibodies

Publications (1)

Publication Number Publication Date
CN102046199A true CN102046199A (zh) 2011-05-04

Family

ID=41091567

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980109905XA Pending CN102046199A (zh) 2008-03-20 2009-03-20 使用抗mif抗体的治疗方法
CN2009801093284A Pending CN102088993A (zh) 2008-03-20 2009-03-20 炎症的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009801093284A Pending CN102088993A (zh) 2008-03-20 2009-03-20 炎症的治疗方法

Country Status (14)

Country Link
US (2) US20110044988A1 (enExample)
EP (2) EP2252318A4 (enExample)
JP (2) JP2011526244A (enExample)
KR (1) KR20110014141A (enExample)
CN (2) CN102046199A (enExample)
AU (2) AU2009225389A1 (enExample)
BR (1) BRPI0910259A2 (enExample)
CA (2) CA2717365A1 (enExample)
CO (1) CO6300848A2 (enExample)
EA (1) EA201001529A1 (enExample)
IL (1) IL207752A0 (enExample)
MX (1) MX2010010198A (enExample)
NZ (1) NZ588033A (enExample)
WO (2) WO2009117706A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357249A (zh) * 2011-10-26 2012-02-22 广州赫尔氏药物开发有限公司 能够抑制耐药性结核杆菌的药物
CN107964045A (zh) * 2017-12-18 2018-04-27 南京医科大学 一种人鼠嵌合抗CXCR2全分子IgG及其应用
CN112334482A (zh) * 2018-06-07 2021-02-05 翁科奥内研发有限责任公司 用于癌症治疗的抗oxMIF/抗CD3抗体
CN113383235A (zh) * 2018-12-26 2021-09-10 高露洁-棕榄公司 作为牙龈炎诊断物的中性粒细胞失调的生物标志物

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009117706A2 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
WO2009120186A1 (en) * 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
WO2011038149A2 (en) * 2009-09-23 2011-03-31 Carolus Therapeutics, Inc. Methods of treating inflammation
EP2308484A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
EP2696682B1 (en) * 2011-04-13 2018-03-21 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
TWI407964B (zh) * 2011-05-10 2013-09-11 Univ Fu Jen Catholic 干擾性核糖核酸用於治療或減緩疼痛之用途
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US10596233B2 (en) 2011-06-30 2020-03-24 Dignity Health Use of pertussis toxin as a therapeutic agent
WO2013003786A1 (en) * 2011-06-30 2013-01-03 Dignity Health Use of pertussis toxin as a therapeutic agent
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
DK2844250T3 (en) 2012-05-01 2018-01-08 Translatum Medicus Inc METHODS OF TREATMENT AND DIAGNOSTICATION OF EYE DISEASES CONCERNING BLINDNESS
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10316075B2 (en) 2013-10-03 2019-06-11 Oregon Health & Science University Recombinant polypeptides comprising MHC class II α1 domains
EP3242685B1 (en) 2015-01-09 2022-05-04 AdAlta Limited Cxcr4 binding molecules
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3008272A1 (en) * 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
BR112018068393A2 (pt) 2016-03-11 2019-01-15 Ardea Biosciences Inc inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais
KR102645432B1 (ko) * 2016-03-28 2024-03-11 (주)아모레퍼시픽 피부 세포 분화 촉진용 조성물 및 피부 세포 분화 촉진 물질의 스크리닝 방법
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
EP3445402A4 (en) * 2016-04-21 2019-12-11 The Board Of Regents Of The University Of Texas System METHOD AND COMPOSITIONS FOR DETECTING ANEURYSMS
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109890364B (zh) 2016-10-03 2023-10-17 儿童医疗中心公司 糖尿病肾病的预防和治疗
CN108355133A (zh) * 2017-01-26 2018-08-03 中国医学科学院阜外医院 靶向cxcr7的药物组合物和方法
WO2019084313A1 (en) * 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System USE OF SDHA AS PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR UREAL MELANOMA
KR20210009315A (ko) 2018-04-11 2021-01-26 오하이오 스테이트 이노베이션 파운데이션 안약 전달용 서방형 마이크로 입자를 이용한 방법 및 조성물
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110133306B (zh) * 2019-05-09 2023-04-07 北京勤邦生物技术有限公司 检测西马特罗的酶联免疫试剂盒及其应用
EP4117662A4 (en) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. METHODS OF TREATING NEUTROPENIA
MX2022011231A (es) * 2020-03-11 2022-11-07 Biolinerx Ltd Inhibidor de cxcr4 para el tratamiento del sindrome de dificultad respiratoria aguda e infecciones virales.
WO2021219495A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CA3196362A1 (en) * 2020-10-28 2022-05-05 University Health Network (Uhn) Methods of treating spondyloarthritis or symptoms thereof
KR102866709B1 (ko) * 2021-03-22 2025-10-02 클립스비엔씨 주식회사 신규한 재조합 마이코박테리움 스메그마티스 균주 및 이의 용도
EP4320445A1 (en) 2021-04-08 2024-02-14 Joslin Diabetes Center, Inc. Methods of diagnosing and predicting renal decline
KR102561554B1 (ko) * 2021-04-14 2023-07-28 부산대학교 산학협력단 치주질환 진단용 바이오마커 조성물, 치주질환 치료 효용성 평가용 바이오마커 조성물 및 이를 이용한 진단키트
EP4472735A2 (en) * 2022-02-04 2024-12-11 University of Pittsburgh - of the Commonwealth System of Higher Education Methods of detecting and treating cerebral aneurysms
WO2025171411A1 (en) * 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026307A1 (en) * 1993-05-17 1994-11-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
CA2434671A1 (en) * 2001-01-12 2002-09-06 The Picower Institute For Medical Research Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
JP2003226653A (ja) * 2001-11-30 2003-08-12 Jun Nishihira 多発性硬化症治療剤
WO2003047622A1 (fr) * 2001-11-30 2003-06-12 Jun Nishihira Remedes pour la sclerose en plaques
US6656168B2 (en) * 2001-12-18 2003-12-02 Kimberly-Clark Worldwide, Inc. Feminine care product with discrete areas of a skin wellness additive
US20040009149A1 (en) * 2002-02-27 2004-01-15 Altman John D. Multimeric binding complexes
JP4472351B2 (ja) * 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド インターナライジング抗ｃｄ７４抗体およびその使用方法
ES2364155T3 (es) * 2002-11-25 2011-08-25 Jallal Messadek Composiciones de betaína y ácido acetilsalicílico.
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
WO2005065328A2 (en) * 2003-12-30 2005-07-21 The United States Of America, As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
WO2006105666A1 (en) * 2005-04-06 2006-10-12 Queen's University At Kingston Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007138961A1 (ja) * 2006-05-29 2007-12-06 Redox Bioscience Inc. マクロファージ遊走阻止因子によって引き起こされる障害の予防乃至治療剤
WO2009117706A2 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
WO2009120186A1 (en) * 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
WO2010065491A2 (en) * 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357249A (zh) * 2011-10-26 2012-02-22 广州赫尔氏药物开发有限公司 能够抑制耐药性结核杆菌的药物
CN107964045A (zh) * 2017-12-18 2018-04-27 南京医科大学 一种人鼠嵌合抗CXCR2全分子IgG及其应用
CN107964045B (zh) * 2017-12-18 2021-04-23 南京医科大学 一种人鼠嵌合抗CXCR2全分子IgG及其应用
CN112334482A (zh) * 2018-06-07 2021-02-05 翁科奥内研发有限责任公司 用于癌症治疗的抗oxMIF/抗CD3抗体
CN113383235A (zh) * 2018-12-26 2021-09-10 高露洁-棕榄公司 作为牙龈炎诊断物的中性粒细胞失调的生物标志物
CN113383235B (zh) * 2018-12-26 2024-07-26 高露洁-棕榄公司 作为牙龈炎诊断物的中性粒细胞失调的生物标志物

Also Published As

Publication number Publication date
JP2011515416A (ja) 2011-05-19
US20110044988A1 (en) 2011-02-24
WO2009117706A3 (en) 2010-01-21
CO6300848A2 (es) 2011-07-21
AU2009225385A1 (en) 2009-09-24
EP2252318A2 (en) 2010-11-24
KR20110014141A (ko) 2011-02-10
WO2009117710A3 (en) 2010-01-21
WO2009117706A2 (en) 2009-09-24
WO2009117710A2 (en) 2009-09-24
EP2254597A2 (en) 2010-12-01
CA2717071A1 (en) 2009-09-24
CA2717365A1 (en) 2009-09-24
EA201001529A1 (ru) 2011-06-30
EP2254597A4 (en) 2012-04-18
AU2009225389A1 (en) 2009-09-24
IL207752A0 (en) 2010-12-30
CN102088993A (zh) 2011-06-08
MX2010010198A (es) 2010-12-21
BRPI0910259A2 (pt) 2015-12-01
EP2252318A4 (en) 2012-04-18
JP2011526244A (ja) 2011-10-06
NZ588033A (en) 2012-11-30
US20110262386A1 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
CN102046199A (zh) 使用抗mif抗体的治疗方法
TWI589587B (zh) 中和性抗－ｃｃｌ２０抗體
US8329178B2 (en) Antibodies against CXCR4 and methods of use thereof
AU2010298249A1 (en) Methods of treating inflammation
US20100040537A1 (en) Prostaglandin E2 Binding Proteins and Uses Thereof
JP2021521843A (ja) 最適化された抗ｔｌ１ａ抗体
JP6779621B2 (ja) ＭＡｄＣＡＭアンタゴニストの投与レジメン
JP2015214563A (ja) アルファ−４−ベータ−７ヘテロ二量体特異的アンタゴニスト抗体
JP2012505160A (ja) 炎症を処置する方法
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
JP2020504078A (ja) レプチン受容体をアンタゴナイズする抗原結合性タンパク質
JP2021515770A (ja) 抗ｉｌ−２３特異的抗体を用いたクローン病の治療方法
JP2022502417A (ja) 抗ｏｘ４０抗体、その抗原結合フラグメント、および医薬用途
JP2016222656A (ja) 炎症性腸疾患を抑制する抗体および該抗体を含む医薬組成物
KR20220054600A (ko) Il-38-특이적 항체
TW202302635A (zh) Ｉｌ－３８專一性抗體

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110504